Disease that damages the myelin sheaths around nerves
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: references that do not meet Wikipedia's guidelines for medical content, or are excessively dated, are contained in this article. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Multiple sclerosis" – news · newspapers · books · scholar · JSTOR(July 2022)
CD68-stained tissue shows several macrophages in the area of a demyelinated lesion caused by MS.
Specialty
Neurology
Symptoms
Variable, including almost any neurological symptom or sign, with autonomic, visual, motor, and sensory problems being the most common.[1]
Usual onset
Age 20–50[2]
Duration
Long term[3]
Causes
Unknown[4]
Diagnostic method
Based on symptoms and medical tests[5]
Treatment
Disease-modifying therapies[6]
Physiotherapy[7]
Occupational therapy[7]
Frequency
0.032% (world)
Multiple sclerosis (MS) is an autoimmune disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged.[3] This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.[1][8][9] Specific symptoms can include double vision, vision loss, eye pain, muscle weakness, and loss of sensation or coordination.[3][10][11] MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms).[12][13] In the relapsing forms of MS, between attacks, symptoms may disappear completely, although some permanent neurological problems often remain, especially as the disease advances.[13] In the progressive forms of MS, bodily function slowly deteriorates and disability worsens once symptoms manifest and will steadily continue to do so if the disease is left untreated.[14]
While the cause is unclear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells.[4] Proposed causes for this include immune dysregulation, genetics, and environmental factors, such as viral infections.[15][16][8][17] MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.[5]
No cure for multiple sclerosis is known.[18] Current treatments are aimed at mitigating inflammation and resulting symptoms from acute flares and prevention of further attacks with disease-modifying medications.[8][19] Physical therapy[7] and occupational therapy,[20] along with patient-centered symptom management, can help with people's ability to function. The long-term outcome is difficult to predict; better outcomes are more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks.[21]
Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system.[22] Nearly one million people in the United States had MS in 2022,[23] and in 2020, about 2.8 million people were affected globally, with rates varying widely in different regions and among different populations.[24] The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men.[2] MS was first described in 1868 by French neurologist Jean-Martin Charcot.[25]
The name "multiple sclerosis" is short for multiple cerebro-spinal sclerosis, which refers to the numerous glial scars (or sclerae – essentially plaques or lesions) that develop on the white matter of the brain and spinal cord.[25]
^ abCompston A, Coles A (October 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–1517. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.
^ abMilo R, Kahana E (March 2010). "Multiple sclerosis: geoepidemiology, genetics and the environment". Autoimmunity Reviews. 9 (5): A387-94. doi:10.1016/j.autrev.2009.11.010. PMID 19932200.
^ abc"NINDS Multiple Sclerosis Information Page". National Institute of Neurological Disorders and Stroke. 19 November 2015. Archived from the original on 13 February 2016. Retrieved 6 March 2016.
^ abNakahara J, Maeda M, Aiso S, et al. (February 2012). "Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy". Clinical Reviews in Allergy & Immunology. 42 (1): 26–34. doi:10.1007/s12016-011-8287-6. PMID 22189514. S2CID 21058811.
^ abTsang BK, Macdonell R (December 2011). "Multiple sclerosis- diagnosis, management and prognosis". Australian Family Physician. 40 (12): 948–955. PMID 22146321. Archived from the original on 5 October 2021. Retrieved 28 December 2023.
^Liu Z, Liao Q, Wen H, et al. (June 2021). "Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis". Autoimmunity Reviews. 20 (6): 102826. doi:10.1016/j.autrev.2021.102826. PMID 33878488. S2CID 233325057.
^ abcAlphonsus KB, Su Y, D'Arcy C (April 2019). "The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis". Complementary Therapies in Medicine. 43: 188–195. doi:10.1016/j.ctim.2019.02.010. PMID 30935529. S2CID 86669723.
^ abcCompston A, Coles A (April 2002). "Multiple sclerosis". Lancet. 359 (9313): 1221–1231. doi:10.1016/S0140-6736(02)08220-X. PMID 11955556. S2CID 14207583.
^Murray ED, Buttner EA, Price BH (2012). "Depression and Psychosis in Neurological Practice". In Daroff R, Fenichel G, Jankovic J, Mazziotta J (eds.). Bradley's neurology in clinical practice (6th ed.). Philadelphia, PA: Elsevier/Saunders. ISBN 978-1-4377-0434-1.
^Piryonesi SM, Rostampour S, Piryonesi SA (April 2021). "Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms". Multiple Sclerosis and Related Disorders. 49: 102740. doi:10.1016/j.msard.2021.102740. PMID 33450500. S2CID 231624230.
^Mazumder R, Murchison C, Bourdette D, et al. (25 September 2014). "Falls in people with multiple sclerosis compared with falls in healthy controls". PLOS ONE. 9 (9): e107620. Bibcode:2014PLoSO...9j7620M. doi:10.1371/journal.pone.0107620. PMC 4177842. PMID 25254633.
^ ab[medical citation needed]Lublin FD, Reingold SC (April 1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 46 (4): 907–911. doi:10.1212/WNL.46.4.907. PMID 8780061. S2CID 40213123.
^Loma I, Heyman R (September 2011). "Multiple sclerosis: pathogenesis and treatment". Current Neuropharmacology. 9 (3): 409–416. doi:10.2174/157015911796557911. PMC 3151595. PMID 22379455.
^Ward M, Goldman MD (August 2022). "Epidemiology and Pathophysiology of Multiple Sclerosis". Continuum. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. PMID 35938654. S2CID 251375096.
^Aloisi F, Cross AH (October 2022). "MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis". Journal of Neuroimmunology. 371: 577935. doi:10.1016/j.jneuroim.2022.577935. PMID 35931008. S2CID 251152784.
^Ascherio A, Munger KL (April 2007). "Environmental risk factors for multiple sclerosis. Part I: the role of infection". Annals of Neurology. 61 (4): 288–299. doi:10.1002/ana.21117. PMID 17444504. S2CID 7682774.
^"NINDS Multiple Sclerosis Information Page". National Institute of Neurological Disorders and Stroke. 19 November 2015. Archived from the original on 13 February 2016. Retrieved 6 March 2016.
^McGinley MP, Goldschmidt CH, Rae-Grant AD (February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765–779. doi:10.1001/jama.2020.26858. PMID 33620411. S2CID 232019589.
^Quinn É, Hynes SM (July 2021). "Occupational therapy interventions for multiple sclerosis: A scoping review". Scandinavian Journal of Occupational Therapy. 28 (5): 399–414. doi:10.1080/11038128.2020.1786160. hdl:10379/16066. PMID 32643486. S2CID 220436640.
^Weinshenker BG (1994). "Natural history of multiple sclerosis". Annals of Neurology. 36 (Suppl): S6-11. doi:10.1002/ana.410360704. PMID 8017890. S2CID 7140070.
^Berer K, Krishnamoorthy G (November 2014). "Microbial view of central nervous system autoimmunity". FEBS Letters. 588 (22): 4207–13. doi:10.1016/j.febslet.2014.04.007. PMID 24746689. S2CID 2772656.
^McGinley MP, Goldschmidt CH, Rae-Grant AD (February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765–779. doi:10.1001/jama.2020.26858. PMID 33620411. S2CID 232019589.
^Lane J, Ng HS, Poyser C, et al. (July 2022). "Multiple sclerosis incidence: A systematic review of change over time by geographical region". Mult Scler Relat Disord. 63: 103932. doi:10.1016/j.msard.2022.103932. PMID 35667315. S2CID 249188137.
^ abClanet M (June 2008). "Jean-Martin Charcot. 1825 to 1893". International MS Journal. 15 (2): 59–61. PMID 18782501. Archived from the original (PDF) on 30 March 2019. Retrieved 21 October 2010. * Charcot J (1868). "Histologie de la sclerose en plaques". Gazette des Hopitaux, Paris. 41: 554–5.
and 28 Related for: Multiple sclerosis information
Multiplesclerosis (MS) is an autoimmune disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts...
Multiplesclerosis can cause a variety of symptoms: changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, or difficulty moving;...
Nucleus Node of Ranvier Axon terminal Schwann cell Myelin sheath Multiplesclerosis is an inflammatory demyelinating disease of the CNS in which activated...
Multiplesclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist,...
Tumefactive multiplesclerosis is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics...
Several biomarkers for diagnosis of multiplesclerosis, disease evolution and response to medication (current or expected) are under research. While most...
Current standards for diagnosing multiplesclerosis (MS) are based on the 2018 revision of McDonald criteria. They rely on MRI detection (or clinical demonstration)...
Research in multiplesclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying...
acute multiplesclerosis, also known as Marburg multiplesclerosis or acute fulminant multiplesclerosis, is considered one of the multiplesclerosis borderline...
Multiplesclerosis (MS) can be pathologically defined as the presence of distributed glial scars (scleroses) in the central nervous system that must show...
MultipleSclerosis Society may refer to: The MultipleSclerosis Society of Great Britain The MultipleSclerosis Society of Canada The National Multiple...
Malignant multiplesclerosis is used to describe MS patients who reach significant level of disability in a short period of time. Malignant MS cases are...
The National MultipleSclerosis Society (NMSS) is a nonprofit organization founded in 1946. It is an organization dedicated to supporting individuals affected...
This is a list of notable people with multiplesclerosis, a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal...
treatment of adults with highly active forms of relapsing-remitting multiplesclerosis. Cladribine is a purine analogue that selectively targets and suppresses...
often grouped together under MultipleSclerosis. They are sometimes considered different diseases from MultipleSclerosis, but considered by others to...
There are several ways for pharmaceuticals for treating multiplesclerosis (MS) to reach the market. Novel pharmaceuticals cannot enter the US market without...
University of Pennsylvania. Banwell is the co-director of the Pediatric MultipleSclerosis and Neuroinflammatory Disorders Clinic at the Children's Hospital...
MultipleSclerosis Australia, or MS Australia, is a national non-profit organization in Australia that coordinates and allocates funds for multiple sclerosis...
The MultipleSclerosis Trust (MS Trust) is an independent, national UK charity that was established in 1993. The MS Trust works to provide information...
in the CSF of more than 95% of patients with clinically definite multiplesclerosis. Two methods of analysis are possible: (a) protein electrophoresis...
Lausberg H (2020). "What's in a name? That which we call MultipleSclerosis Fatigue". MultipleSclerosis (Houndmills, Basingstoke, England). 27 (7): 983–988...
of multiplesclerosis organizations in different countries around the world. MultipleSclerosis International Federation European MultipleSclerosis Platform...
The MultipleSclerosis Journal (formerly MultipleSclerosis) is a monthly peer-reviewed medical journal covering the clinical neurology of multiple sclerosis...
The MultipleSclerosis Functional Composite (MSFC) is a clinical trial outcome measure of assessing the severity of multiplesclerosis primarily used in...
BG-12, an oral fumarate, which was being studied for the treatment of multiplesclerosis and psoriasis. In January 2007, the company announced it would acquire...
that dopamine imbalance influences the fatigue in multiplesclerosis. In patients with multiplesclerosis, dopamine inhibits production of IL-17 and IFN-γ...
others, is a medication used to treat chronic lymphocytic leukemia and multiplesclerosis. In chronic lymphocytic leukemia, it has been used as both a first...